Loading the section…

WGS: financial statements from SEC — TradeAlmanac

WGS

GeneDx Holdings Corp.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/12/2025	31/12/2024
Revenue	428M	305M
Cost of revenue	129M	111M
Gross profit	298M	194M
Research and development	72M	46M
Selling, general and administrative	151M	105M
Operating income	−13M	−23M
Pre-tax income	−21M	−53M
Income tax	−116,000	−343,000
Net income	−21M	−52M
Earnings per share	−0.73	−1.94
Earnings per share, diluted	−0.73	−1.94
Weighted average shares	29M	27M
Weighted average shares, diluted	29M	27M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	94M	105M	96M	74M	100M	85M	59M	57M
Short-term investments	77M	66M	59M

Cash flow

Metric	31/12/2025	31/12/2024
Operating cash flow	33M	−28M
Depreciation and amortisation	25M	22M
Share-based compensation	32M	9M
Capital expenditure	19M	5M
Investing cash flow	−62M	−30M
Financing cash flow	48M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator